The deal priced at low end of $5.75-$6.25 target range. JPMorgan, TD Cowen and Piper Sandler are acting as joint book running managers for the offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Therapeutics $75M Spot Secondary; price range $5.75-$6.25
- Protara Therapeutics announces $75M common stock offering
- Protara’s TARA-002: Promising Efficacy and Clear Regulatory Path Justify Buy Rating
- Buy Rating for Protara Therapeutics Driven by Promising Bladder Cancer Drug Trial
- Buy Recommendation for Protara Therapeutics Driven by Promising TARA-002 Developments and Strategic Market Positioning